CIK 0001885522 · Non-accelerated filer<br>Smaller reporting company
Neumora Therapeutics, Inc.
Sign in to watch- Ticker
- NMRA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 844367680
- Phone
- (857) 760-0900
- Business address
- 260 ARSENAL PLACE, SUITE 1, WATERTOWN, MA, 02472
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $481,506
- in 2 filings
Net −$481,506. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-02-13 | BERNS PAUL L See Remarks | Grant or award · Stock Option (Right to Buy) | +955,864 | 955,864 | ||
| 2025-02-13 | BERNS PAUL L See Remarks | Grant or award · Stock Option (Right to Buy) | +342,500 | 342,500 | ||
| 2025-02-13 | Lenz Robert A. Head of R&D | Returned to the company · Stock Option (Right to Buy) | −502,934 | 0 | ||
| 2025-02-13 | Lenz Robert A. Head of R&D | Returned to the company · Stock Option (Right to Buy) | −100,000 | 0 | ||
| 2025-02-13 | Lenz Robert A. Head of R&D | Grant or award · Stock Option (Right to Buy) | +502,934 | 502,934 | ||
| 2025-02-13 | Lenz Robert A. Head of R&D | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2025-02-13 | Piacquad David Director | Returned to the company · Stock Option (Right to Buy) | −46,455 | 0 | ||
| 2025-02-13 | Piacquad David Director | Returned to the company · Stock Option (Right to Buy) | −28,571 | 0 | ||
| 2025-02-13 | Piacquad David Director | Grant or award · Stock Option (Right to Buy) | +46,455 | 46,455 | ||
| 2025-02-13 | Piacquad David Director | Grant or award · Stock Option (Right to Buy) | +28,571 | 28,571 | ||
| 2025-02-13 | Aurora Daljit Singh See Remarks | Grant or award · Stock Option (Right to Buy) | +1,000,000 | 1,000,000 | ||
| 2025-02-13 | Aurora Daljit Singh See Remarks | Returned to the company · Stock Option (Right to Buy) | −40,890 | 0 | ||
| 2025-02-13 | Aurora Daljit Singh See Remarks | Returned to the company · Stock Option (Right to Buy) | −137,538 | 0 | ||
| 2025-02-13 | Aurora Daljit Singh See Remarks | Returned to the company · Stock Option (Right to Buy) | −207,901 | 0 | ||
| 2025-02-13 | Aurora Daljit Singh See Remarks | Returned to the company · Stock Option (Right to Buy) | −136,210 | 0 | ||
| 2025-02-13 | Aurora Daljit Singh See Remarks | Returned to the company · Stock Option (Right to Buy) | −72,221 | 0 | ||
| 2025-02-13 | Aurora Daljit Singh See Remarks | Returned to the company · Stock Option (Right to Buy) | −29,737 | 0 | ||
| 2025-02-13 | Aurora Daljit Singh See Remarks | Returned to the company · Stock Option (Right to Buy) | −195,000 | 0 | ||
| 2025-02-13 | Aurora Daljit Singh See Remarks | Grant or award · Stock Option (Right to Buy) | +40,890 | 40,890 | ||
| 2025-02-13 | Aurora Daljit Singh See Remarks | Grant or award · Stock Option (Right to Buy) | +137,538 | 137,538 |
Page 10 of 20 · 384 trades